Equillium, Inc. Common Stock (EQ) Stock
Key stats
- Market cap
- $111.28M
- Price / Earnings ratio
- -5.1x
- EPS (TTM)
- -$0.14
- Volume
- Loading
- 52-week high
- $3.54
- 52-week low
- $0.76
Source: third-party data provider, as of November 13, 2026
Compare with EQ
Recent news
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
EQ
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
EQ
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
EQ
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
EQNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.63
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.03
- SMA 50
- $1.63
- Price below SMA 50
- EMA 50
- $1.61
- Price below EMA 50
- SMA 200
- $2.09
- Price below SMA 200
- EMA 200
- $1.82
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
EQEQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
EQEquillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
EQThese Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
EQ
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
EQNews tone: automated (AI) classification of the article's content, not a price prediction.
About Equillium, Inc. Common Stock
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Bruce Steel | Co-Founder, CEO & Director | 1966 |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior VP & COO | 1970 |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & President | 1981 |
| Ms. Penny Tom CPA | Senior VP of Finance & Principal Accounting Officer | — |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications | — |
| Ms. Snehal Naik Ph.D. | Chief Development Officer | — |
| Dr. Lisette Acevedo | Vice President of Clinical Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.63
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.03
- SMA 50
- $1.63
- Price below SMA 50
- EMA 50
- $1.61
- Price below EMA 50
- SMA 200
- $2.09
- Price below SMA 200
- EMA 200
- $1.82
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $9.00
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.5 | +0.0 | +39.4 | +3.9 | -27.6 | +3.2 | -26.2 | -11.0 | +2.9 |
